Clinical audit of current Helicobacter pylori treatment outcomes in Singapore by Tiing Leong Ang, Kim Wei Lim, Daphne Ang, Yu Jun Wong, Malcolm Tan, Andrew Siang Yih Wong

Subjects: “…first line treatment…”
Get full text

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data by Petra Belohlavkova, Daniela Zackova, Hana Klamova, Edgar Faber, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Ivana Jeziskova, Katerina Machova Polakova, Pavel Zak, Tereza Jurkova, Marika Chrapava, Jiri Mayer

Subjects: Get full text

Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer by Julien Taieb, Marwan Fakih, Gabor Liposits, Gerald W. Prager, Eric Van Cutsem, Fortunato Ciardiello, Nadia Amellal, Elizabeth Calleja, Mei Liu, Lucas Roby, Josep Tabernero, Thierry André

Subjects: Get full text

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations by Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan

Subjects: Get full text

Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data by Zhihao Li, Daniel Aliseda, Owen Jones, Luckshi Rajendran, Christian Magyar, Robert Grant, Grainne M. O’Kane, Anna Saborowski, Gonzalo Sapisochin, Arndt Vogel

Subjects: Get full text

Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer by Guisen Yin, Xin Liu, Xiangtao Yu, Song Tan, Fen Liu

Subjects: Get full text

Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspec... by Cuicui Yu, Yingqi Wu, Yadi Geng, Hui Yan, Pengli Zhu, Peng Ji, Fei Wu, Lijuan Ning, Yubin Feng, Aizong Shen

Subjects: Get full text

Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study by Ilya Tsimafeyeu, Vyacheslav Chubenko, Olga Baklanova, Alexey Kalpinskiy, Sufia Safina, Andrei Lebedinets, Vladislav Petkau, Elvira Parsadanova, Maria Turganova, Aleksei Shkurat, Natalia Tovbik, Elena Tkacheva, Yulia Anzhiganova, Olga Novikova, Varvara Bragina, Ruslan Zukov, Rashida Orlova

Subjects: Get full text

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer? by Tommaso Porcelli, Cristina Luongo, Anna Cerbone, Carmine Di Luccio, Mariantonia Nacchio, Maria Angela De Stefano, Martin Schlumberger, Domenico Salvatore

Subjects: Get full text

Pre-treatment nutrition-related indicators and the prognosis of patients with newly diagnosed epithelial ovarian cancer: an ambispective cohort study by Shirui Wang, Jingyu Zhu, Ningjuan Wu, Nannan Wang, Xiaohe Dang, Minyi Zhao, Juan Zhao, Ding Ma, Xiaofeng Yang

Subjects: Get full text

First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis by Mengyao Zhang, Lan Sun

Subjects: Get full text

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer by Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

Subjects: Get full text

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence by Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida, Tatsuki Ikoma, Yuki Takeyasu, Utae Katsushima, Hiroshige Yoshioka, Takayasu Kurata

Subjects: Get full text

Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data by Fabrizio Nelli, Enzo Maria Ruggeri, Antonella Virtuoso, Diana Giannarelli, Armando Raso, Federica Natoni, Gloria Pessina, Daniele Remotti, Mario Giovanni Chilelli, Carlo Signorelli, Agnese Fabbri

Subjects: Get full text

First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis by Rong Long, Fangping Chen

Subjects: Get full text